Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURRANCE-1: Rituximab plus cyclophosphamide vs rituximab alone in ANCA-associated vasculitis
2023-507868-39-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) comparing Rituximab plus cyclophosphamide with Rituximab alone (2 arms). Primary endpoint: Number of rituximab retreatment infusions over 2 years. Planned start Aug 2024; status: authorised.
02
Drugs
rituximabcyclophosphamide
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on 2023-507868-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507868-39-00.